GleamWall
中文EN

SMNR Semnur Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1913577 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY87.9%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,344.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,757.8%
Debt / equity—
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-580.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue————————
R&D expense$1.44M$1.25M$1.27M$714,000$1.14M$502,000$187,000$235,000
SG&A expense$2.13M$2.98M$3.31M$5.44M$151.45M$497,000$478,000$541,000
Operating income-$3.58M-$4.22M-$4.58M-$6.16M-$152.59M-$999,000-$665,000-$776,000
Interest expense$56,000$123,000——$0$0$26,974$26,692
Net income-$3.63M-$4.35M-$4.58M-$6.16M-$152.59M-$999,000-$665,000-$167,306
EBITDA-$3.58M-$4.22M-$4.58M-$6.16M-$152.59M-$999,000-$665,000-$776,000
EPS (basic)-0.02-0.02-0.02—-0.76-0.01-0.01—
EPS (diluted)-0.02-0.02-0.02—-0.76-0.01-0.01—
Weighted avg. shares (diluted)224.23M230.21M230.21M—201.69M200.00M200.00M—
Banking
Deposits—————$123,107$120,482$75,292
Balance sheet
Cash & equivalents$54,000$39,000$103,000$20,000$85,000$55,000$7,000$12,000
Current assets$1.26M$1.19M$1.22M$596,000$85,000$14,144$2,736$6.00M
PP&E, net$750,000$750,000$750,000$750,000$689,000——$689,000
Total assets$2.01M$1.94M$1.97M$1.35M$774,000$562,462$9.15M$6.68M
Current liabilities$11.28M$10.67M$10.38M$10.17M$10.03M$8.27M$7.85M$35,000
Total liabilities$35.31M$31.62M$27.30M$22.10M$15.37M$11.16M$10.74M$49.47M
Shareholders' equity-$33.31M-$29.67M-$25.33M-$20.75M-$14.59M-$44.45M-$43.45M-$42.78M
Shares outstanding217.71M230.21M230.21M230.21M229.74M——200.00M
Cash flow statement
Operating cash flow-$2.22M-$2.14M-$2.67M-$3.60M-$2.08M$268,000-$399,000-$1.41M
Investing cash flow———————$0
Financing cash flow$2.24M$2.07M$2.75M$3.54M$10.79M-$220,000$394,000$1.41M
Depreciation & amortization$0$0$0$0$0$0$0$0
Stock-based compensation$855,000$1.29M$1.48M$2.03M$140.19M$119,000$92,000$137,000
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.